National Center for Advancing Translational Sciences; Notice of Closed Meeting, 10081 [2021-03190]
Download as PDF
<![CDATA[
Federal Register / Vol. 86, No. 31 / Thursday, February 18, 2021 / Notices
10081
EARLY TERMINATIONS GRANTED—Continued
[12/01/2020 12:00:00 a.m.,12/31/2020 12:00:00 a.m.]
12/28/2020
20210205
20210689
20210690
20210691
......
......
......
......
G
G
G
G
Caesars Entertainment, Inc.; William Hill PLC; Caesars Entertainment, Inc.
Biogen Inc.; Sage Therapeutics, Inc; Biogen Inc.
Thoma Bravo Fund XIII–A, L.P.; Venafi, Inc; Thoma Bravo Fund XIII–A, L.P.
Nasdaq, Inc.; Verafin Holdings, Inc.; Nasdaq. Inc.
12/31/2020
20210651 ......
20210652 ......
20210653 ......
G
G
G
Stephen Griggs; AdaptHealth Corp.; Stephen Griggs.
SkyKnight Aero Holdings, LLC; AdaptHealth Corp.; SkyKnight Aero Holdings, LLC.
Peloton Equity AeroCare SPV I, L.P.; AdaptHealth Corp.; Peloton Equity AeroCare SPV I, L.P.
1811, Morgantown, West Virginia
26505, Telephone (304) 285–5879.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
FOR FURTHER INFORMATION CONTACT:
Theresa Kingsberry (202–326–3100),
Program Support Specialist, Federal
Trade Commission Premerger
Notification Office, Bureau of
Competition, Room CC–5301,
Washington, DC 20024.
By direction of the Commission.
April J. Tabor,
Secretary.
[FR Doc. 2021–03183 Filed 2–17–21; 8:45 am]
BILLING CODE P
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[FR Doc. 2021–03231 Filed 2–17–21; 8:45 am]
BILLING CODE 4163–18–P
jbell on DSKJLSW7X2PROD with NOTICES
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP)—Funding
Opportunity Announcement (FOA),
RFA OH–21–003, Extension of the
World Trade Center Health Registry
(U50); Amended Notice of Meeting
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
VerDate Sep<11>2014
18:18 Feb 17, 2021
Jkt 253001
National Center for Advancing
Translational Sciences; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Center for
Advancing Translational Sciences Special
Emphasis Panel; CTSA Revision Award.
Date: March 9, 2021.
Time: 12:00 p.m. to 6:00 p.m.
PO 00000
Frm 00048
Fmt 4703
Sfmt 4703
Dated: February 11, 2021.
David W. Freeman,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–03190 Filed 2–17–21; 8:45 am]
BILLING CODE 4140–01–P
National Institutes of Health
Notice is hereby given of a change in
the meeting of the Disease, Disability,
and Injury Prevention and Control
Special Emphasis Panel (SEP)—Funding
Opportunity Announcement (FOA),
RFA OH–21–003, Extension of the
World Trade Center Health Registry
(U50), April 13, 2021; 9:00 a.m.–6:00
p.m., EDT in the original FRN.
The virtual meeting was published in
the Federal Register on Monday,
January 11, 2021, Volume 86, Number 6,
page 1976.
The meeting on April 13, 2021 is
being amended to change the time and
should read as follows:
Time: 1:00 p.m.–3:00 p.m., EDT.
The meeting is closed to the public.
FOR FURTHER INFORMATION CONTACT:
Marilyn Ridenour B.S.N., M.B.A.,
M.P.H., C.P.H., C.I.C., CAPT, USPHS,
Scientific Review Officer, CDC, National
Institute for Occupational Safety and
Health, 1095 Willowdale Road, Mailstop
Agenda: To review and evaluate grant
applications.
Place: National Center for Advancing
Translational Sciences, National Institutes of
Health, 6701 Democracy Boulevard, Room
1078, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Rahat (Rani) Khan, Ph.D.,
Scientific Review Officer, Office of Scientific
Review, National Center for Advancing
Translational Sciences, National Institutes of
Health, 6701 Democracy Boulevard, Room
1078, Bethesda, MD 20892, 301–894–7319
khanr2@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.859, Pharmacology,
Physiology, and Biological Chemistry
Research; 93.350, B—Cooperative
Agreements; 93.859, Biomedical Research
and Research Training, National Institutes of
Health, HHS)
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive
Patent License: Autologous Therapy
for the Treatment of Autoimmune
Disease Using Chimeric Antigen
Receptors Targeting CD19
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The National Cancer Institute,
an institute of the National Institutes of
Health, Department of Health and
Human Services, is contemplating the
grant of an Exclusive Patent License to
practice the inventions embodied in the
Patents and Patent Applications listed
in the Supplementary Information
section of this notice to Kyverna
Therapeutics (‘‘Kyverna’’) located in
Berkeley, CA.
SUMMARY:
E:\FR\FM\18FEN1.SGM
18FEN1
]]>Agencies
[Federal Register Volume 86, Number 31 (Thursday, February 18, 2021)]
[Notices]
[Page 10081]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-03190]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Center for Advancing Translational Sciences; Notice of
Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Center for Advancing Translational
Sciences Special Emphasis Panel; CTSA Revision Award.
Date: March 9, 2021.
Time: 12:00 p.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Center for Advancing Translational Sciences,
National Institutes of Health, 6701 Democracy Boulevard, Room 1078,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Rahat (Rani) Khan, Ph.D., Scientific Review
Officer, Office of Scientific Review, National Center for Advancing
Translational Sciences, National Institutes of Health, 6701
Democracy Boulevard, Room 1078, Bethesda, MD 20892, 301-894-7319
[email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.859,
Pharmacology, Physiology, and Biological Chemistry Research; 93.350,
B--Cooperative Agreements; 93.859, Biomedical Research and Research
Training, National Institutes of Health, HHS)
Dated: February 11, 2021.
David W. Freeman,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2021-03190 Filed 2-17-21; 8:45 am]
BILLING CODE 4140-01-P
